Post Mortem for a Diagnostics Company by a Founding Investor

On-Q-ity, a Cancer Diagnostic Company: R.I.P. | LifeSciVC. Lots of lessons from this story, but two of the key ones are: 1. Clinical trials are costly and risky. The company’s first investments were in 4 clinical trials for their most promising biomarkers, all...

Genetic Analysis is Already a Commodity Product

Interesting opinion piece rebutting an open letter from Peter Meldrum, CEO of Myriad, in advance of the Supreme Court’s decision on the patentability of BRCA1/BRCA2. Myriad Genetics CEO Claims He Owns Your Genes – Forbes. Patents support the public good...